Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The biotech could be a winner over the long run but faces some significant challenges.

What Are the Prospects for Inovio's COVID Vaccine?

There was one big wrinkle with the biotech's study.

Why Investors Didn't Like Inovio's Seemingly Positive Clinical Results

INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead The post Sell Inovio While You Still Can appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

Sell Inovio While You Still Can

The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten trading days, while it's down 14% over the last five trading days, but we believe the stock, after the.

Can Inovio Pharmaceuticals Stock Recover After The Recent 25% Drop?

Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

Inovio Is Still Working On Finishing A Midstage Covid Vaccine Test — Is It A Buy?

PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing. The...

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

Investors still appear to have doubts about two of the biotech's lead candidates.

Why Inovio Stock Is Tanking Today

Better-than-expected top- and bottom-line results weren't enough.

Why Inovio's Positive Q4 Update Didn't Impress Investors

Inovio Pharmaceuticals' (INO) CEO Joseph Kim on Q4 2020 Results - Earnings Call Transcript

Novavax

Roku

Zoom Video

These are the stocks posting the largest moves after the bell on Monday, March 1.

Stocks making the biggest moves after the bell: Zoom, Roku, Novavax & more

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are lower in after-hours trading in reaction to multiple catalysts. REVEAL 1 Study Reveals Mixed Results In Cervical Dysplasia: Inovio said a pivotal REVEAL 1 Phase 3 study of VGX-3100 in treating high-grade precancerous cervical dysplasia, caused by HPV-16 and/or HV-18 met primary and secondary endpoints among all evaluable subjects.

Inovio Reports Q4 Earnings Beat, Mixed REVEAL 1 Data And Coronavirus Vaccine Update

Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved higher  in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 63.16% over the past year to ($0.14), which beat the estimate of ($0.22).

Recap: Inovio Pharmaceuticals Q4 Earnings

PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial...

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

On Monday, March 01, Inovio Pharmaceuticals (NASDAQ:INO) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Earnings Outlook For Inovio Pharmaceuticals

Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Inovio (INO) This Earnings Season?

QIAGEN

Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products using next-generation sequencing technology to complement Inovio's therapies. The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from the clinical use of VGX-3100, INO's immunotherapy, to treat advanced cervical dysplasia associated with the human papillomavirus (HPV).

Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop...

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.

Inovio (INO) to Report Q4 Earnings: What's in the Cards?

This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.

Are Short-Sellers Right About Inovio?

Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.

Inovio Pharmaceuticals (INO) Dips More Than Broader Markets: What You Should Know

Vaxart

The choice isn't easy, but simplicity may be the answer.

Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart

Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street.  Bullish Analyst, Fund Stake Prop Up Stock: Oppenheimer analyst Hartaj Singh initiated coverage of Inovio shares with an Outperform rating and $35 price target in a Thursday note.

Inovio Shares Rally As Oppenheimer Says Coronavirus Vaccine Developer Approaching Finish Line

An analyst is really bullish about the biotech stock.

Why Inovio Pharmaceuticals Stock Is Soaring Today

Disney

Fisker Inc

Hyliion

One of the most common questions traders have about stocks is “Why Is It Moving?”. That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

News for Inovio Pharmaceuticals Stock (INO)